title: Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
authors.forename: Y L
authors.initials: YL
authors.lastname: Chee
authors.forename: M A
authors.initials: MA
authors.lastname: Vickers
authors.forename: D
authors.initials: D
authors.lastname: Stevenson
authors.forename: T L
authors.initials: TL
authors.lastname: Holyoake
authors.forename: D J
authors.initials: DJ
authors.lastname: Culligan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D002999:Clone Cells / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000473:pathology; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate